Mark Cabonce

Mark Cabonce joined NAMSA in March 2025 after the acquisition of WuXi AppTec’s U.S. Medical Device Testing operations. He had been with WuXi AppTec since 2015 and now supports clients as a Principal Toxicologist, specializing in medical devices and combination products.

Before joining WuXi AppTec, Mr. Cabonce was a toxicologist managing regulated in vivo and in vitro acute toxicology studies, assessing formulation dossiers for G.H.S. classification and labeling, and preparing risk assessments supporting domestic and international product registrations.

Mr. Cabonce also managed pharmacokinetic and preclinical safety evaluation studies for a broad range of pharmaceutical and agrichemical clients under prevailing EPA, FDA and OECD guidelines. Mr. Cabonce earned a master’s degree in biology from St. Louis University and has been a Diplomate of the American Board of Toxicology since 2005.